According to Verastem Oncology 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.28146. At the end of 2022 the company had a P/E ratio of -1.06.
Year | P/E ratio | Change |
---|---|---|
2022 | -1.06 | -78.81% |
2021 | -5.00 | 24.41% |
2020 | -4.02 | 502.83% |
2019 | -0.6667 | -77.58% |
2018 | -2.97 | 69.5% |
2017 | -1.75 | 53.5% |
2016 | -1.14 | -0.46% |
2015 | -1.15 | -74% |
2014 | -4.42 | -29.51% |
2013 | -6.26 | 21.14% |
2012 | -5.17 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
-0.3480 | -72.84% | ๐บ๐ธ USA | |
14.5 | -1,231.10% | ๐บ๐ธ USA | |
30.9 | -2,509.77% | ๐บ๐ธ USA | |
9.49 | -840.74% | ๐ฌ๐ง UK |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.